CAN-2409 is also being evaluated in multiple phase 2 and phase 3 clinical trials for lung, brain, pancreatic, and prostate cancers.
but we will have more new data and a new cohort of 11 patients in December this year."
Recent CADL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 12:31:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 12:29:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 12:28:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 12:24:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/17/2024 11:32:16 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/17/2024 11:31:21 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/17/2024 11:29:48 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/17/2024 11:27:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 12:36:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 12:35:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 12:34:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 12:30:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 11:38:54 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 11:37:48 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 11:36:16 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 11:33:31 AM
- Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Candel Therapeutics to Join Russell 3000® Index • GlobeNewswire Inc. • 06/11/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/30/2024 09:20:30 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/30/2024 08:30:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:15:12 PM
- FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/24/2024 11:30:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:05:10 PM
- Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:00:00 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM